Abstract Radiotherapy is one of the main treatment for esophageal cancer. With the development of radiotherapy techniques, prognostic outcomes of esophageal cancer have been gradually improved and radiation-induced heart disease (RIHD) has captivated increasing attention. Radiation-induced heart complications mainly encompass pericardial disease, cardiomyopathy, coronary artery atherosclerosis, valvular heart disease, and arrhythmias, etc. The use of modern radiotherapy techniques is expected to mitigate heart injury and reduce the risk of RIHD. Research progress on the incidence and risk factors of RIHD in esophageal cancer were described as follows.
Corresponding Authors:
Sun Yunchuan, Email:sunyunchuan@163.com
Cite this article:
Yang Hongjuan,Sun Yunchuan. Research progress on radiation-induced heart disease in esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 585-588.
Yang Hongjuan,Sun Yunchuan. Research progress on radiation-induced heart disease in esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(6): 585-588.
[1] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer[J]. N Engl J Med, 2013, 368(11):987-998. DOI:10.1056/NEJMoa1209825. [2] van den Bogaard VA, Ta BD, van der Schaaf A, et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures[J]. J Clin Oncol, 2017, 35(11):1171-1178. DOI:10.1200/JCO.2016.69.8480. [3] Hahn E, Jiang H, Ng A, et al. Late cardiac toxicity after mediastinal radiation therapy for Hodgkin lymphoma:contributions of coronary artery and whole heart dose-volume variables to risk prediction[J]. Int J Radiat Oncol Biol Phys, 2017, 98(5):1116-1123. DOI:10.1016/j.ijrobp.2017.03.026. [4] van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma[J]. J Clin Oncol, 2016, 34(3):235-243. DOI:10.1200/JCO.2015.63.4444. [5] Wang H, Wei J, Zheng Q, et al. Radiation-induced heart disease:a review of classification, mechanism and prevention[J]. Int J Biol Sci, 2019, 15(10):2128-2138. DOI:10.7150/ijbs.35460. [6] Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet, 2005, 366:2087-2106. DOI:10.1016/S0140-6736(05)67887-7. [7] Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage Ⅲ non-small-cell lung cancer:pooled analysis of dose-escalation trials delivering 70 to 90Gy[J]. J Clin Oncol, 2017, 35(13):1387-1394. DOI:10.1200/JCO.2016.70.0229. [8] Gharzai L, Verma V, Denniston KA, et al. Radiation therapy and cardiac death in long-term survivors of esophageal cancer:an analysis of the surveillance, epidemiology, and end result database[J]. PLoS One, 2016, 11(7):e0158916. DOI:10.1371/journal.pone.0158916. [9] Zamorano JL, Lancellotti P, Rodriguez MunozD, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016;37(36):2768-2801. DOI:10.1093/eurheartj/ehw211. [10] Beukema JC, van Luijk P, Widder J, et al. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?[J]. Radiother Oncol, 2015, 114(1):85-90. DOI:10.1016/j.radonc.2014.11.037. [11] Sio TT, Wilson ZC, Stauder MC, et al. Long-term treatment outcomes for locally advanced esophageal cancer:a single-institution experience[J]. Am J Clin Oncol, 2016, 39(5):448-452. DOI:10.1097/COC.0000000000000089. [12] Frandsen J, Boothe D, Gaffney DK, et al. Increased risk of death due to heart disease after radiotherapy for esophageal cancer[J]. J Gastrointest Oncol, 2015, 6(5):516-523. DOI:10.3978/j.issn.2078-6891.2015.040. [13] Wei X, Liu HH, Tucker SL, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy[J]. Int J Radiat Oncol Biol Phys, 2008, 70(3):707-714. DOI:10.1016/j.ijrobp.2007.10.056. [14] Fukada J, Shigematsu N, Takeuchi H, et al. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients[J]. Int J Radiat Oncol Biol Phys, 2013, 87(3):487-493. DOI:10.1016/j.ijrobp.2013.07.008. [15] Ogino I, Watanabe S, Sakamaki K, et al. Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer[J]. Strahlenther Onkol, 2017, 193(7):552-560. DOI:10.1007/s00066-017-1127-8. [16] Hayashi Y, Ⅱjima H, Isohashi F, et al. The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer:a retrospective cohort study[J]. BMC Cancer, 2019, 19(1):195. DOI:10.1186/s12885-019-5421-y. [17] Konski A, Li T, Christensen M, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer[J]. Radiother Oncol, 2012, 104(1):72-77. DOI:10.1016/j.radonc.2012.04.016. [18] Tait LM, Meyer JE, McSpadden E, et al. Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma[J]. Pract Radiat Oncol, 2013, 3(4):e149-155. DOI:10.1016/j.prro.2013.02.001. [19] Lester SC, Lin SH, Chuong M, et al. A multi-institutional analysis of trimodality therapy for esophageal cancer in elderly patients[J]. Int J Radiat Oncol Biol Phys, 2017, 98(4):820-828. DOI:10.1016/j.ijrobp.2017.02.021. [20] Morota M, Gomi K, Kozuka T, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 75(1):122-128. DOI:10.1016/j.ijrobp.2008.10.075. [21] Chen YJ, Liu A, Han C, et al. Helical tomotherapy for radiotherapy in esophageal cancer:a preferred plan with better conformal target coverage and more homogeneous dose distribution[J]. Med Dosim, 2007, 32(3):166-171. DOI:10.1016/j.meddos.2006.12.003. [22] Choi KH, Kim J, Lee SW, et al. Dosimetric comparison between modulated arc therapy and static intensity modulated radiotherapy in thoracic esophageal cancer:a single institutional experience[J]. Radiat Oncol J, 2018, 36(1):63-70. DOI:10.3857/roj.2017.00241. [23] Kataria T, Govardhan HB, Gupta D, et al. Dosimetric comparison between volumetric modulated arc therapy (VMAT) vs. intensity modulated radiation therapy (IMRT) for radiotherapy of mid esophageal carcinoma[J]. J Cancer Res Ther, 2014, 10(4):871-877. DOI:10.4103/0973-1482.138217. [24] Wu Z, Xie C, Hu M, et al. Dosimetric benefits of IMRT and VMAT in the treatment of middle thoracic esophageal cancer:is the conformal radiotherapy still an alternative option?[J]. J Appl Clin Med Phys, 2014, 15(3):93–101. DOI:10.1120/jacmp.v15i3.4641. [25] Xu C, Xi M, Komaki R, et al. Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus[J]. Adv Radiat Oncol, 2017, 2(3):325-332. DOI:10.1016/j.adro.2017.03.006. [26] Hirano Y, Onozawa M, Hojo H, et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma[J]. Radiat Oncol, 2018, 13(1):23. DOI:10.1186/s13014-018-0966-5. [27] Ling TC, Slater JM, Nookala P, et al. Analysis of intensity-modulated radiation therapy (IMRT), proton and 3D conformal radiotherapy (3D-CRT) for reducing perioperative cardiopulmonary complications in esophageal cancer patients[J]. Cancers (Basel), 2014, 6(4):2356-2368. DOI:10.3390/cancers6042356. [28] Shiraishi Y, Xu C, Yang J, et al. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or intensity-modulated radiation therapy[J]. Radiother Oncol, 2017, 125(1):48-54. DOI:10.1016/j.radonc.2017.07.034. [29] Venkat PS, Shridhar R, Naghavi AO, et al. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer[J]. Dis Esophagus, 2017, 30(7):1-9. DOI:10.1093/dote/dox036. [30] Davis M, Witteles RM. Radiation-induced heart disease:an under-recognized entity?[J]. Curr Treat Options Cardiovasc Med, 2014, 16(6):317. DOI:10.1007/s11936-014-0317-2. [31] 陈偲晔, 王淑莲. 乳腺癌放射性心脏损伤(RIHD)的评估和预防研究进展[J]. 中华放射肿瘤学杂志, 2017, 26(4):474-480. DOI:10.3760/cma.j.issn.1004-4221.2017.04.024. Chen SY, Wang SL. Research advances in the evaluation and prevention of radiation-induced heart damage in breast cancer[J]. Chin J Radiat Oncol,2017, 26(4):474-480. DOI:10.3760/cma.j.issn.1004-4221.2017.04.024.
2022, Vol. 31 
